$ENTO
Entero Therapeutics Inc

2024 Q1 Form 10-K Financial Statement

#000141057824000364 Filed on March 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.660M $2.786M $10.74M
YoY Change 220.64% 27.94% -10.42%
% of Gross Profit
Research & Development $566.0K $1.307M $5.033M
YoY Change -58.44% 1184.02% -42.65%
% of Gross Profit
Depreciation & Amortization $12.29K $9.270K $29.27K
YoY Change 68.4% 26.64% 0.93%
% of Gross Profit
Operating Expenses $9.226M $4.094M $15.77M
YoY Change 127.1% 79.57% 24.39%
Operating Profit -$9.226M -$15.77M
YoY Change 127.1% 24.39%
Interest Expense $66.20K -$6.830K -$19.93K
YoY Change 636.64% 355.33% -225.51%
% of Operating Profit
Other Income/Expense, Net -$66.63K -$500.00 -$4.220K
YoY Change 709.76% -99.97% -99.78%
Pretax Income -$9.292M -$4.101M -$15.79M
YoY Change 128.28% 2.88% 7.97%
Income Tax -$14.90M
% Of Pretax Income
Net Earnings $5.568M -$4.178M -$16.10M
YoY Change -236.77% 4.87% 10.07%
Net Earnings / Revenue
Basic Earnings Per Share $3.12 -$47.88
Diluted Earnings Per Share $0.38 -$5.35 -$47.88
COMMON SHARES
Basic Shares Outstanding 2.025M 13.50M 336.3K
Diluted Shares Outstanding 14.51M 336.3K

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.432M $3.712M $3.712M
YoY Change 66.24% 172.34% 172.34%
Cash & Equivalents $3.400M $3.700M
Short-Term Investments
Other Short-Term Assets $4.058M $1.244M $1.244M
YoY Change 180.75% -36.4% -36.4%
Inventory
Prepaid Expenses $4.058M $1.244M
Receivables
Other Receivables
Total Short-Term Assets $7.490M $4.956M $4.956M
YoY Change 112.19% 45.23% 45.23%
LONG-TERM ASSETS
Property, Plant & Equipment $25.75K $210.0K $210.0K
YoY Change -29.5% 379.05% -30.71%
Goodwill $20.04M $1.684M
YoY Change 1089.81% 0.0%
Intangibles $63.37M
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.77K $32.77K $32.77K
YoY Change -17.39% -17.37% -17.37%
Total Long-Term Assets $83.64M $1.927M $1.927M
YoY Change 4073.63% -4.93% -4.93%
TOTAL ASSETS
Total Short-Term Assets $7.490M $4.956M $4.956M
Total Long-Term Assets $83.64M $1.927M $1.927M
Total Assets $91.13M $6.883M $6.883M
YoY Change 1546.81% 26.54% 26.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.997M $554.3K $554.3K
YoY Change 325.01% -23.02% -23.02%
Accrued Expenses $2.554M $892.4K $892.4K
YoY Change 202.04% 178.72% 130.99%
Deferred Revenue
YoY Change
Short-Term Debt $386.8K $612.8K $612.8K
YoY Change 1.68% 1.54% 1.54%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.173M $3.133M $3.133M
YoY Change 135.18% 26.17% 26.17%
LONG-TERM LIABILITIES
Long-Term Debt $6.398M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $127.6K $147.0K $147.0K
YoY Change -35.08% -31.35% -31.35%
Total Long-Term Liabilities $6.398M $147.0K $147.0K
YoY Change 3155.59% -31.35% -31.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.173M $3.133M $3.133M
Total Long-Term Liabilities $6.398M $147.0K $147.0K
Total Liabilities $13.27M $3.280M $3.280M
YoY Change 370.34% 21.6% 21.6%
SHAREHOLDERS EQUITY
Retained Earnings -$178.8M -$184.3M
YoY Change 3.59% 9.35%
Common Stock $203.00 $156.00
YoY Change 30.97% 56.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.18M $3.603M $3.603M
YoY Change
Total Liabilities & Shareholders Equity $91.13M $6.883M $6.883M
YoY Change 1546.81% 26.54% 26.54%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income $5.568M -$4.178M -$16.10M
YoY Change -236.77% 4.87% 10.07%
Depreciation, Depletion And Amortization $12.29K $9.270K $29.27K
YoY Change 68.4% 26.64% 0.93%
Cash From Operating Activities -$3.747M -$3.438M -$12.38M
YoY Change 31.68% -38.53% -44.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $88.17K -$500.0K -$500.0K
YoY Change
Cash From Investing Activities $88.17K -$500.0K -$500.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $15.83M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.379M 4.357M 15.23M
YoY Change -4.74% -21.13% -3.26%
NET CHANGE
Cash From Operating Activities -3.747M -3.438M -12.38M
Cash From Investing Activities 88.17K -500.0K -500.0K
Cash From Financing Activities 3.379M 4.357M 15.23M
Net Change In Cash -279.9K 418.9K 2.349M
YoY Change -139.89% -715.53% -135.56%
FREE CASH FLOW
Cash From Operating Activities -$3.747M -$3.438M -$12.38M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Registrant Name
EntityRegistrantName
First Wave BioPharma, Inc.
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001604191
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1560998
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49750
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.050
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1428
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1560998
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49750
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37853
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4993860
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
777 Yamato Road, Suite 502
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
CY2023 dei City Area Code
CityAreaCode
561
CY2023 dei Local Phone Number
LocalPhoneNumber
589-7020
CY2023 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
FWBI
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
6700000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2025199
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
339
CY2023 dei Auditor Name
AuditorName
Mazars USA LLP
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3711770
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1362910
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
93014
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1244466
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1956831
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4956236
CY2022Q4 us-gaap Assets Current
AssetsCurrent
3412755
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14565
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43839
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
21522
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
21513
CY2023Q4 us-gaap Goodwill
Goodwill
1684182
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
195440
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
259261
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11250
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
18149
CY2023Q4 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1912394
CY2022Q4 fwbi Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1983105
CY2023Q4 us-gaap Assets
Assets
6883195
CY2022Q4 us-gaap Assets
Assets
5439699
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
554277
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
720040
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
825290
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320176
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
1069616
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
761488
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
612784
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
603494
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
67111
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
66151
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4239
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12138
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3133317
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2483487
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
146949
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
214060
CY2023Q4 us-gaap Liabilities
Liabilities
3280266
CY2022Q4 us-gaap Liabilities
Liabilities
2697547
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1560998
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49750
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
156
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
187931445
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171275836
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184328672
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168533689
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3602929
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6883195
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5439699
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5033218
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8776302
CY2022 fwbi Research And Development Recovery Expenses Intellectual Property Acquired
ResearchAndDevelopmentRecoveryExpensesIntellectualPropertyAcquired
-8085045
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10737609
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11986809
CY2023 us-gaap Operating Expenses
OperatingExpenses
15770827
CY2022 us-gaap Operating Expenses
OperatingExpenses
12678066
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-15770827
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-12678066
CY2023 us-gaap Interest Expense
InterestExpense
22463
CY2022 us-gaap Interest Expense
InterestExpense
15879
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
2531
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
8415
CY2022 fwbi Gain Loss On Dissolution Of Foreign Subsidiary
GainLossOnDissolutionOfForeignSubsidiary
-1711371
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4224
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-232741
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24156
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1951576
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-15794983
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14629642
CY2022 fwbi Other Comprehensive Income Loss From Dissolution Of Foreign Subsidiary Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossFromDissolutionOfForeignSubsidiaryNetOfTaxPortionAttributableToParent
1711371
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-487236
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15794983
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13405507
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-15794983
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14629642
CY2022 fwbi Deemed Dividends On Warrant Modification
DeemedDividendsOnWarrantModification
47300
CY2023 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
308128
CY2022 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
296127
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16103111
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14973069
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
336342
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
336342
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35912
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35912
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-47.88
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-47.88
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-416.94
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-416.94
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
CY2023 fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
657
CY2023 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
-308128
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
93201
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1040472
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-15794983
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3602929
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7821550
CY2022 fwbi Issuance Of Stock And Warrants For Cash Net Of Offering Costs
IssuanceOfStockAndWarrantsForCashNetOfOfferingCosts
178336
CY2022 fwbi Issuance Of Stock For Cash Net Of Offering Costs
IssuanceOfStockForCashNetOfOfferingCosts
20663
CY2022 fwbi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
7971931
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7691221
CY2022 fwbi Common Stock And Pre Funded Warrants Issued Upon Exercise Amount
CommonStockAndPreFundedWarrantsIssuedUponExerciseAmount
48419
CY2022 fwbi Deemed Dividend Of Series B Preferred Stock
DeemedDividendOfSeriesBPreferredStock
296127
CY2022 fwbi Warrant Modification
WarrantModification
47300
CY2022 fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200490
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
769124
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationTax
1711371
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-487236
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14629642
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2742152
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-15794983
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-14629642
CY2023 us-gaap Depreciation
Depreciation
29274
CY2022 us-gaap Depreciation
Depreciation
29271
CY2023 fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
63821
CY2022 fwbi Change In Right Of Use Assets
ChangeInRightOfUseAssets
76936
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1040472
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
769124
CY2022 fwbi Realized Foreign Currency Translation Loss From Dissolution Of Subsidiary
RealizedForeignCurrencyTranslationLossFromDissolutionOfSubsidiary
1711371
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
93201
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
200490
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-93014
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
93014
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-712365
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
177069
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-66151
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-108916
CY2023 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-6899
CY2022 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-25863
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-165763
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1987691
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1617898
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-73077
CY2022 fwbi Increase Decrease In Payables Related To Acquisition
IncreaseDecreaseInPayablesRelatedToAcquisition
-8085045
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-7899
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2680
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12377852
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22344079
CY2023 fwbi Payment Made Related To License Agreement
PaymentMadeRelatedToLicenseAgreement
500000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000
CY2022 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
198999
CY2023 fwbi Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
5524900
CY2022 fwbi Proceeds From Issuance Of Common Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfOfferingCosts
15357083
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
10304658
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
657
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
48419
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
7691221
CY2022 fwbi Payment Made Related To Acquisition Agreement
PaymentMadeRelatedToAcquisitionAgreement
6914955
CY2023 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-603494
CY2022 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-641236
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15226721
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15739531
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2348869
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6604548
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-259713
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1384423
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8248684
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3733292
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1384423
CY2023 us-gaap Interest Paid Net
InterestPaidNet
22463
CY2022 us-gaap Interest Paid Net
InterestPaidNet
15879
CY2022 fwbi Deemed Dividend On Warrant Modifications
DeemedDividendOnWarrantModifications
47300
CY2023Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
308128
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
296127
CY2023 us-gaap Notes Issued1
NotesIssued1
683001
CY2022 us-gaap Notes Issued1
NotesIssued1
677027
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3700000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184300000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3700000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-184300000
CY2023Q4 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
20
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates.</p>
CY2023Q4 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
20
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000.00
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At December 31, 2023 and 2022, the Company had approximately $3.7 million and $0.9 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</p>
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3700000
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
900000
CY2023 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
612784
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
603494
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
73253
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43979
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14565
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43839
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
CY2021Q4 us-gaap Goodwill
Goodwill
1911705
CY2022 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-227523
CY2022Q4 us-gaap Goodwill
Goodwill
1684182
CY2023Q4 us-gaap Goodwill
Goodwill
1684182
CY2023 fwbi Stock Cancelled During Period Shares Acquisitions
StockCancelledDuringPeriodSharesAcquisitions
481
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
108797
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
495741
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
253577
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
309867
CY2023Q4 fwbi Consulting Fees
ConsultingFees
75972
CY2022Q4 fwbi Consulting Fees
ConsultingFees
4969
CY2022Q4 fwbi Clinical Trials
ClinicalTrials
5340
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
825290
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
320176
CY2023Q4 fwbi Note Payables
NotePayables
613000
CY2022Q4 fwbi Note Payables
NotePayables
603000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
20
CY2023Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
7
CY2022Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1560998
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49750
CY2023Q4 fwbi Preferred Stock Remaining Authorized But Unissued
PreferredStockRemainingAuthorizedButUnissued
9999485.04
CY2022Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
5000000.0
CY2022Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
383.20
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
5000000.0
CY2022 fwbi Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-47000.000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y6M
CY2023 fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
3132614
CY2023 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
9.17
CY2023 fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P4Y9M21D
CY2023 fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
3
CY2023 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-107100.00
CY2023 fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
1461628
CY2023 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-14.84
CY2023 fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y6M25D
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1779780
CY2023Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
19.29
CY2023 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P4Y11M26D
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1110
CY2021Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
39858.00
CY2021 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y11M12D
CY2022 fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
139899
CY2022 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted
75.00
CY2022 fwbi Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm
P5Y4M24D
CY2022 fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
33
CY2022 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpired
-22057.00
CY2022 fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
32179
CY2022 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
-1.60
CY2022 fwbi Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P5Y4M9D
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
108797
CY2022Q4 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
383.20
CY2022 fwbi Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P5Y6M
CY2023 fwbi Class Of Warrant Or Right Grants In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageGrantDateFairValue
22.78
CY2022 fwbi Class Of Warrant Or Right Grants In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageGrantDateFairValue
4090.40
CY2023 fwbi Class Of Warrant Or Right Fair Value Assumptions Expected Term
ClassOfWarrantOrRightFairValueAssumptionsExpectedTerm
P5Y
CY2022 fwbi Class Of Warrant Or Right Fair Value Assumptions Expected Term
ClassOfWarrantOrRightFairValueAssumptionsExpectedTerm
P5Y14D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
61.00
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4473.60
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1040472
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
769124
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
500000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
CY2023Q4 fwbi Number Of Real Property Operating Leases
NumberOfRealPropertyOperatingLeases
1
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
154000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
157000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0700
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
86202
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
88788
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
60593
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
235583
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21523
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
214060
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33500000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29500000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33400000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29500000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4000000.0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2100000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23080000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18916000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
234000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
733000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5399000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
5708000
CY2023Q4 fwbi Deferred Tax Assets Deferred Expense Capitalized Research And Development
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopment
2586000
CY2022Q4 fwbi Deferred Tax Assets Deferred Expense Capitalized Research And Development
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopment
2022000
CY2023Q4 fwbi Deferred Tax Assets Research And Development Credits
DeferredTaxAssetsResearchAndDevelopmentCredits
2087000
CY2022Q4 fwbi Deferred Tax Assets Research And Development Credits
DeferredTaxAssetsResearchAndDevelopmentCredits
1715000
CY2022Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
318000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
87000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
102000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
33473000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29514000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
33425000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
29450000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
48000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
64000
CY2023Q4 fwbi Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
48000
CY2022Q4 fwbi Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
64000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
48000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
64000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.028
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.049
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.087
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.252
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.146
CY2023 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.005
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.077
CY2022 fwbi Effective Income Tax Rate Reconciliation Dissolution Of Foreign Subsidiary Percent
EffectiveIncomeTaxRateReconciliationDissolutionOfForeignSubsidiaryPercent
-0.459
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.025
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.044
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
2100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16103111
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14973069
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
336342
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35912
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
336342
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35912
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-47.88
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-416.94
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-47.88
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-416.94
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1832622
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
109160
CY2023 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.06
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
87000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
112000

Files In Submission

Name View Source Status
0001410578-24-000364-index-headers.html Edgar Link pending
R33.htm Edgar Link pending
0001410578-24-000364-index.html Edgar Link pending
0001410578-24-000364.txt Edgar Link pending
0001410578-24-000364-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fwbi-20231231.xsd Edgar Link pending
fwbi-20231231x10k.htm Edgar Link pending
fwbi-20231231xex10d53.htm Edgar Link pending
fwbi-20231231xex14d1.htm Edgar Link pending
fwbi-20231231xex14d1001.jpg Edgar Link pending
fwbi-20231231xex19d1.htm Edgar Link pending
fwbi-20231231xex19d1001.jpg Edgar Link pending
fwbi-20231231xex21d1.htm Edgar Link pending
fwbi-20231231xex23d1.htm Edgar Link pending
fwbi-20231231xex31d1.htm Edgar Link pending
fwbi-20231231xex31d2.htm Edgar Link pending
fwbi-20231231xex32d1.htm Edgar Link pending
fwbi-20231231xex4d31.htm Edgar Link pending
fwbi-20231231xex97d1.htm Edgar Link pending
fwbi-20231231xex97d1001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
fwbi-20231231_cal.xml Edgar Link unprocessable
fwbi-20231231_def.xml Edgar Link unprocessable
fwbi-20231231_lab.xml Edgar Link unprocessable
fwbi-20231231_pre.xml Edgar Link unprocessable
fwbi-20231231x10k_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable